Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
Shiramoto M, Eto T, Irie S, Fukuzaki A, Teichert L, Tillner J, Takahashi Y, Koyama M, Dahmen R, Heise T, Becker RH. Shiramoto M, et al. Among authors: dahmen r. Diabetes Obes Metab. 2015 Mar;17(3):254-60. doi: 10.1111/dom.12415. Epub 2014 Dec 22. Diabetes Obes Metab. 2015. PMID: 25425297 Free PMC article. Clinical Trial.
Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
Bailey TS, Pettus J, Roussel R, Schmider W, Maroccia M, Nassr N, Klein O, Bolli GB, Dahmen R. Bailey TS, et al. Among authors: dahmen r. Diabetes Metab. 2018 Feb;44(1):15-21. doi: 10.1016/j.diabet.2017.10.001. Epub 2017 Nov 16. Diabetes Metab. 2018. PMID: 29153485 Free article. Clinical Trial.
Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator.
Visentin R, Giegerich C, Jäger R, Dahmen R, Boss A, Grant M, Dalla Man C, Cobelli C, Klabunde T. Visentin R, et al. Among authors: dahmen r. Diabetes Technol Ther. 2016 Sep;18(9):574-85. doi: 10.1089/dia.2016.0128. Epub 2016 Jun 22. Diabetes Technol Ther. 2016. PMID: 27333446 Free PMC article.
Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF.
Bode D, Semmler L, Wakula P, Hegemann N, Primessnig U, Beindorff N, Powell D, Dahmen R, Ruetten H, Oeing C, Alogna A, Messroghli D, Pieske BM, Heinzel FR, Hohendanner F. Bode D, et al. Among authors: dahmen r. Cardiovasc Diabetol. 2021 Jan 7;20(1):7. doi: 10.1186/s12933-020-01208-z. Cardiovasc Diabetol. 2021. PMID: 33413413 Free PMC article.
55 results